Insider Transactions in Q2 2023 at Amylyx Pharmaceuticals, Inc. (AMLX)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 22
2023
|
Margaret Olinger Chief Commercial Officer |
SELL
Bona fide gift
|
Direct |
1,580
-0.68%
|
-
|
|
May 17
2023
|
Gina Mazzariello Chief Legal Officer |
SELL
Bona fide gift
|
Direct |
500
-0.9%
|
-
|
|
May 16
2023
|
James M Frates Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
32,500
-18.59%
|
$877,500
$27.27 P/Share
|
|
May 16
2023
|
James M Frates Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,500
+26.93%
|
$195,000
$6.88 P/Share
|
|
May 15
2023
|
Patrick D Yeramian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,965
-5.43%
|
$346,985
$29.03 P/Share
|
|
May 15
2023
|
Patrick D Yeramian Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,965
+2.64%
|
$35,895
$3.63 P/Share
|
|
Apr 17
2023
|
Patrick D Yeramian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
49,579
-9.62%
|
$1,487,370
$30.74 P/Share
|
|
Apr 17
2023
|
Patrick D Yeramian Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
49,579
+8.42%
|
$148,737
$3.63 P/Share
|